Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44.2M
-
Number of holders
-
58
-
Total 13F shares, excl. options
-
31.2M
-
Shares change
-
-668K
-
Total reported value, excl. options
-
$188M
-
Value change
-
-$4.39M
-
Number of buys
-
25
-
Number of sells
-
-27
-
Price
-
$6.04
Significant Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q4 2022
64 filings reported holding PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share as of Q4 2022.
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) has 58 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.2M shares
of 44.2M outstanding shares and own 70.6% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (10.1M shares), ORBIMED ADVISORS LLC (10M shares), FMR LLC (4.59M shares), UBS ASSET MANAGEMENT AMERICAS INC (2.34M shares), VANGUARD GROUP INC (899K shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (515K shares), BlackRock Inc. (394K shares), PRICE T ROWE ASSOCIATES INC /MD/ (301K shares), Candriam S.C.A. (180K shares), and BANK OF AMERICA CORP /DE/ (158K shares).
This table shows the top 58 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.